5d ago
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2026 — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C. Wainwright 28**th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.
Mr. Kohli’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026, and he will be available for one-on-one meeting with investors throughout the conference. Investors that are interested in arranging a meeting can register for the conference here or should contact their H.C. Wainwright representative.
About Grace Therapeutics
Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.
For more information, please visit: www.gracetx.com.
Grace Therapeutics Contact
Prashant Kohli
Chief Executive Officer
Tel: 609-322-1602
Email: [email protected]
Investor Relations
LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: [email protected]
Summary
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C. Wainwright 28 th Annual Global Investment Conference , to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.